• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Pacira touts Phase IV study of Exparel anesthetic in total knee arthroplasty

March 14, 2017 By Sarah Faulkner

Pacira touts Phase IV study of Exparel anesthetic in total knee arthroplastyPacira Pharmaceuticals (NSDQ:PCRX) said today the Phase IV study of its Exparel bupivacaine liposome injection in patients undergoing total knee arthroplasty met its co-primary endpoints for postsurgical pain and opioid reduction.

The anesthetic achieved statistical significance for secondary endpoints including time to 1st opioid use and the percentage of patients who did not require opioids following the procedure.

The 139 patients were randomized to an Exparel-based or a bupivacaine-based multimodal pain regimen of oral acetaminophen, celecoxib and pregabalin, according to Pacira.

The Parsippany, N.J.-based company said it analyzed pain intensity scores from 12 to 48 hours following surgery and the total opioid consumption as morphine equivalents from zero to 48 hours after surgery.

Patients who received Exparel achieved a statistically significant reduction in pain scores compared to their counterparts in the control group. The researchers also concluded that those who were treated with Exparel used significantly fewer opioids than patients who did not in the 2 days following surgery.

“The operating room is the gateway to opioid abuse and places patients at serious risk for addiction and dependence,” chairman & CEO Dave Stack said in prepared remarks. “The results of this study provide further evidence that Exparel effectively reduces, and in some cases, eliminates the use of opioids while providing prolonged postsurgical pain relief to patients undergoing complex and painful knee replacement surgery with a simple inexpensive multimodal design. A recent survey determined that one in 10 opioid naïve patients are opioid dependent 6 months after opioid-driven postsurgical pain management – we believe Exparel can play a critical role in taking on this national issue.”

Filed Under: Clinical Trials, Featured, Pain Management, Surgical Tagged With: Pacira Pharmaceuticals

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS